Nomura Holdings Inc. Raises Position in Moderna, Inc. $MRNA

Key Points

• Nomura Holdings Inc. increased its stake in Moderna by 107.1%, owning a total of 30,826 shares worth $874,000 after purchasing an additional 15,938 shares in the 1st quarter.
• Institutional investors now hold 75.33% of Moderna's stock, with notable increases in stakes from multiple firms, including Voloridge Investment Management and Jump Financial LLC.
• Moderna's stock currently has an average price target of $42.88, with a consensus rating of "Hold" from analysts, despite recent target price adjustments from various brokerage firms.

Nomura Holdings Inc. grew its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 107.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,826 shares of the company's stock after buying an additional 15,938 shares during the period. Nomura Holdings Inc.'s holdings in Moderna were worth $874,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Ameriprise Financial Inc. increased its stake in Moderna by 10.8% in the fourth quarter. Ameriprise Financial Inc. now owns 235,280 shares of the company's stock valued at $9,784,000 after acquiring an additional 23,007 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Moderna by 8.3% in the 4th quarter. Cetera Investment Advisers now owns 40,783 shares of the company's stock worth $1,696,000 after purchasing an additional 3,121 shares in the last quarter. Crestline Management LP bought a new position in shares of Moderna during the 4th quarter valued at about $796,000. Collar Capital Management LLC purchased a new position in shares of Moderna during the 4th quarter valued at about $898,000. Finally, Deutsche Bank AG raised its holdings in shares of Moderna by 54.7% during the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after buying an additional 669,614 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Moderna stock traded up $0.86 during trading hours on Friday, reaching $25.14. The stock had a trading volume of 13,009,398 shares, compared to its average volume of 9,059,473. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $79.96. The company has a fifty day simple moving average of $28.84 and a 200-day simple moving average of $28.50.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on MRNA shares. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. Bank of America lowered their price objective on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Barclays reduced their target price on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a report on Monday, August 4th. Cowen began coverage on shares of Moderna in a research report on Sunday, July 13th. They issued a "hold" rating on the stock. Finally, Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average target price of $42.88.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.